Mylan releases HIV/AIDS medication
Mylan Inc. is launching nevirapine tablets 200 mg, indicated for the combination antiretroviral (ARV) treatment of HIV-1 infection. The company said Wednesday that its Mylan Pharmaceuticals Inc. has begun shipping the medication after receiving final approval from the Food and Drug Administration.